NASDAQ:HJLI
Delisted
Hancock Jaffe Laboratories Inc. Stock News
$5.98
+0.180 (+3.10%)
At Close: Aug 17, 2022
Hancock Jaffe to Participate in the Duologue Series Virtual Webinar Hosted by Ladenburg Thalmann
09:00am, Friday, 24'th Sep 2021
Live webinar followed by Q&A on Monday, September 27th at 1:00 PM ET with Robert Berman Chief Executive Officer of Hancock Jaffe Laboratories IRVINE, CA / ACCESSWIRE / September 24, 2021 / Hancock Jaf
Hancock Jaffe To Rebrand As enVVeno Medical
07:09am, Wednesday, 22'nd Sep 2021
Hancock Jaffe Laboratories Inc (NASDAQ: HJLI) will change its name to enVVeno Medical Corporation and start under a new ticker, "NVNO," from October 1. The Company will also narrow its strategic f
Hancock Jaffe to Host Corporate Update Conference Call and Webcast on September 21, 2021
08:05am, Wednesday, 15'th Sep 2021
Conference call with live video webcast to be held on Tuesday, September 21st at 4:30 p.m. ET IRVINE, CA / ACCESSWIRE / September 15, 2021 / Hancock Jaffe Laboratories, Inc. (NASDAQ:HJLI) ("Hancock Ja
Hancock Jaffe Laboratories: Developing Nature-Mimetic Bioprosthetics
07:43pm, Wednesday, 08'th Sep 2021
Hancock Jaffe Laboratories develops nature-mimetic bioprosthetics for patients with debilitating cardiovascular diseases. The Company got IDE approval in April 2021 to begin a pivotal trial of VenoVal
Hancock Jaffe Laboratories Announces $20 Million Registered Direct Offering Priced At-the-Market Under NASDAQ Rules
08:05am, Tuesday, 07'th Sep 2021
IRVINE, CA / ACCESSWIRE / September 7, 2021 / Hancock Jaffe Laboratories, Inc. (NASDAQ:HJLI), a developer of medical devices that restore cardiac and vascular health, today announced that it has enter
Hancock Jaffe Highlights Two-Year Data For Venous Insufficiency Valve
11:49am, Thursday, 19'th Aug 2021
Hancock Jaffe Laboratories Inc (NASDAQ: HJLI) announced two-year data post-VenoValve implantation in eight patients. Data will be presented at the Society for Vascular Surgery (SVS) Annual Meeting.
Hancock Jaffe Presents New Positive Two-Year VenoValve Data at the Society for Vascular Surgery Annual Meeting
08:00am, Thursday, 19'th Aug 2021
Two-year VenoValve® data shows average improvements in reflux, disease manifestations and pain, of 63%, 60%, and 93%, respectively Patients with venous ulcers who experienced dramatic ulcer healing h
HJLI Stock Price Increases Over 35% Pre-Market: Why It Happened
08:35am, Tuesday, 03'rd Aug 2021
The stock price of Hancock Jaffe Laboratories Inc (NASDAQ: HJLI) increased by over 35% pre-market. This is why it happened.
FDA Grants Breakthrough Device Designation Status for Hancock Jaffe's VenoValve
08:05am, Tuesday, 03'rd Aug 2021
- Goal of FDA Breakthrough Device Program is to speed up development by giving priority to devices that treat life-threatening or irreversibly debilitating conditions - Company preparing to begin SAVV
Hancock Jaffe to Present at the Ladenburg Thalmann 2021 Healthcare Conference
09:05am, Thursday, 08'th Jul 2021
Live webcast on Tuesday, July 13th at 1:00 PM ET IRVINE, CA / ACCESSWIRE / July 8, 2021 / Hancock Jaffe Laboratories, Inc. (NASDAQ:HJLI) ("Hancock Jaffe" or the "Company"), a developer of medical devi
First U.S. Patent Issues on Hancock Jaffe VenoValve
01:40pm, Wednesday, 07'th Apr 2021
IRVINE, CA / ACCESSWIRE / April 7, 2021 / Hancock Jaffe Laboratories, Inc. (NASDAQ:HJLI), a developer of medical devices that restore cardiac and vascular health, today announced that the United State
Hancock Jaffe Receives IDE Approval To Begin VenoValve U.S. Pivotal Trial
07:30am, Monday, 05'th Apr 2021
IRVINE, CA / ACCESSWIRE / April 5, 2021 / Hancock Jaffe Laboratories, Inc. (NASDAQ:HJLI), a developer of medical devices that restore cardiac and vascular health, today announced that the U.S. Food an
Hancock Jaffe Submits IDE Application to FDA for VenoValve U.S. Pivotal Trial
08:30am, Monday, 08'th Mar 2021
IRVINE, CA / ACCESSWIRE / March 8, 2021 / Hancock Jaffe Laboratories, Inc. (NASDAQ:HJLI), a developer of medical devices that restore cardiac and vascular health, today announced that it has submitted
Hancock Jaffe Concludes Successful VenoValve Pre-IDE Meeting with FDA
08:30am, Tuesday, 12'th Jan 2021
Company to Move Forward with Application for VenoValve U.S. Pivotal Trial IRVINE, CA / ACCESSWIRE / January 12, 2021 / Hancock Jaffe Laboratories, Inc. (NASDAQ:HJLI), a developer of medical devices
Hancock Jaffe Announces Executive Promotions
04:15pm, Wednesday, 30'th Dec 2020
IRVINE, CA / ACCESSWIRE / December 30, 2020 / Hancock Jaffe Laboratories, Inc. (NASDAQ:HJLI), a developer of medical devices that restore cardiac and vascular health, today announced that Dr. Hame
